Takeda Pharmaceutical Company Ltd
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
Clinical Trials
1.3k
Trial Phases
5 Phases
Drug Approvals
6
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (1015 trials with phase data)• Click on a phase to view related trials
A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)
- Conditions
- Von Willebrand Disease (VWD)
- Interventions
- First Posted Date
- 2025-08-19
- Last Posted Date
- 2025-08-19
- Lead Sponsor
- Takeda
- Target Recruit Count
- 20
- Registration Number
- NCT07129343
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
- Conditions
- Nonsegmental Vitiligo
- Interventions
- Other: Placebo
- First Posted Date
- 2025-08-07
- Last Posted Date
- 2025-08-15
- Lead Sponsor
- Takeda
- Target Recruit Count
- 200
- Registration Number
- NCT07108283
- Locations
- 🇺🇸
Dermatology Trial Associates, Bryant, Arkansas, United States
🇺🇸First OC Dermatology, Fountain Valley, California, United States
🇺🇸Center for Dermatology Clinical Research, Inc., Fremont, California, United States
A Study to Evaluate How Ontamalimab Works and Assess Its Safety and Tolerability in People With Nonalcoholic Steatohepatitis With Fibrosis Stages 1 to 4
- First Posted Date
- 2025-07-06
- Last Posted Date
- 2025-08-19
- Lead Sponsor
- Takeda
- Target Recruit Count
- 11
- Registration Number
- NCT07052682
- Locations
- 🇺🇸
Arizona Liver Health, Chandler, Arizona, United States
🇺🇸Adobe Clinical Research, LLC, Tucson, Arizona, United States
🇺🇸Southern California Research Center, Coronado, California, United States
A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults
- Conditions
- Dengue Fever
- Interventions
- Biological: Tetravalent Dengue Vaccine (TDV)
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 496
- Registration Number
- NCT07047521
A Study to Monitor the Fruzaqla Treatment of Adults With Metastatic Colorectal Cancer (mCRC) in South Korea
- Conditions
- Colorectal Cancer
- First Posted Date
- 2025-06-25
- Last Posted Date
- 2025-08-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 600
- Registration Number
- NCT07035886
- Prev
- 1
- 2
- 3
- 4
- 5
- 199
- Next
News
Takeda Appoints Former Eli Lilly Executive Rhonda Pacheco to Lead U.S. Operations
Takeda has appointed Rhonda Pacheco, former group vice president of U.S. Cardiometabolic Health at Eli Lilly, as president of its U.S. Business Unit effective September 29, 2025.
ArcaScience Secures $7M to Accelerate AI-Driven Drug Safety Evaluation Platform
ArcaScience raised $7 million in seed funding to expand its AI platform that transforms drug benefit-risk assessments from months-long processes to seconds-long computations.
Controlled Release Drug Delivery Market Expands with Major Pharma Investment in Precision Medicine Technologies
Major pharmaceutical companies including AbbVie, AstraZeneca, and Merck are actively developing controlled drug release systems to enhance treatment of chronic diseases, cancer, and neurological disorders.
GIST Treatment Pipeline Shows Robust Activity with 28+ Therapies in Development Across Multiple Clinical Phases
DelveInsight's 2025 pipeline analysis reveals 25+ companies developing 28+ therapies for gastrointestinal stromal tumors, indicating strong industry investment in this rare cancer space.
FDA Approves Nipocalimab for Myasthenia Gravis as Pipeline Advances with 20+ Novel Therapies
The FDA approved nipocalimab (Imaavy) in May 2025 as the first therapy targeting the underlying cause of generalized myasthenia gravis in patients aged 12 and older with specific antibodies.
Cosmo Pharmaceuticals and Takeda Renew Multi-Year Manufacturing Agreement for Ulcerative Colitis Treatment
Cosmo Pharmaceuticals N.V. and Takeda have renewed their multi-year manufacturing and supply agreement for Mesalazine MMX 1200 mg, an oral once-daily treatment for ulcerative colitis.
AC Immune Reports Strong Immunogenicity Data for Parkinson's Disease Vaccine in Phase 2 Trial
AC Immune's ACI-7104.056 anti-alpha-synuclein active immunotherapy demonstrated a 20-fold increase in anti-alpha-synuclein antibodies after four immunizations in the Phase 2 VacSYn trial for early Parkinson's disease.
Polpharma Biologics and Fresenius Kabi Partner on Vedolizumab Biosimilar for Inflammatory Bowel Disease
Polpharma Biologics has signed a global licensing agreement with Fresenius Kabi for PB016, a proposed biosimilar to Entyvio (vedolizumab) targeting moderate-to-severe ulcerative colitis and Crohn's disease.
Osteosarcoma Market Poised for Significant Growth Through 2034 as Novel Therapies Enter Pipeline
The osteosarcoma market in the 7MM is expected to grow significantly by 2034, driven by extensive R&D activities and the entry of novel therapies including OST-HER2, Naxitamab 15-096, and HALMB-0168.
FDA Clears Takeda's HyHub Devices to Streamline At-Home HYQVIA Immunoglobulin Therapy
The FDA has granted 510(k) clearance to Takeda's HyHub and HyHub Duo devices, which enable needle-free transfer of HYQVIA's dual-vial components for patients aged 17 and older.